Payment overview · 2025
General Payments
$436.10
23 reported records · 13 companies
Healthcare provider profile · identity verified
James Joseph Poock, MD
Allopathic & Osteopathic Physicians|Family Medicine · WATERLOO, IA · NPI 1740260074
Verified facts
What the public records show
CMS Open Payments records show James Joseph Poock, MD received $436.10 in general payments during 2025 across 23 reported records.
Alexion Pharmaceuticals, Inc. accounted for 17.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENBREL as an associated drug or biological on 9330 records involving 2094 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Enbrel by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $78.01 | 17.9% | 4 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $66.08 | 15.2% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $54.58 | 12.5% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $47.62 | 10.9% | 3 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $31.88 | 7.3% | 2 | 2025 |
| Alvogen Inc | Unresolved — no canonical attribution shown | $23.48 | 5.4% | 1 | 2025 |
| KYOWA KIRIN, INC. | Unresolved — no canonical attribution shown | $22.39 | 5.1% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $21.30 | 4.9% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $19.54 | 4.5% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.52 | 4.5% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $18.95 | 4.3% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.31 | 4.0% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $15.44 | 3.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $436.10 | 23 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| STRENSIQ Normalized: strensiq |
Biological | Alexion Pharmaceuticals, Inc. | $78.01 | 4 | 2025 |
Source payment records
|
|||||
| TERIPARATIDE Normalized: teriparatide |
Drug | Almatica Pharma LLC, Alvogen Inc | $55.36 | 3 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $39.72 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $37.86 | 2 | 2025 |
Source payment records
|
|||||
| CRYSVITA Normalized: crysvita |
Drug | KYOWA KIRIN, INC. | $22.39 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $21.45 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $21.30 | 1 | 2025 |
Source payment records
|
|||||
| PENMENVY Normalized: penmenvy |
Biological | GlaxoSmithKline, LLC. | $21.30 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $21.30 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $19.54 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $19.54 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $19.52 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $18.95 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $17.31 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $17.14 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $17.14 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $16.72 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $16.72 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAMAX Normalized: vyndamax |
Drug | PFIZER INC. | $15.70 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $15.44 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $14.78 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $14.78 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 73 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 39 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | ENBREL open payments reported associated product |
CMS Open Payments — General Payments 9330 supporting records · 2094 recipient NPIs · example record 1226877474 |
Enbrel · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
63 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
73 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 333 | 94 |
| Levothyroxine Sodium | Levothyroxine Sodium | 298 | 80 |
| Losartan Potassium | Losartan Potassium | 265 | 68 |
| Lisinopril | Lisinopril | 261 | 66 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 250 | 70 |
| Metoprolol Succinate | Metoprolol Succinate | 249 | 55 |
| Omeprazole | Omeprazole | 221 | 57 |
| Amlodipine Besylate | Amlodipine Besylate | 217 | 64 |
| Trazodone Hcl | Trazodone Hcl | 186 | 52 |
| Pantoprazole Sodium | Pantoprazole Sodium | 174 | 41 |
| Tramadol Hcl | Tramadol Hcl | 165 | 31 |
| Metformin Hcl | Metformin Hcl | 157 | 44 |
| Furosemide | Furosemide | 139 | 41 |
| Meloxicam | Meloxicam | 139 | 43 |
| Tamsulosin Hcl | Tamsulosin Hcl | 134 | 37 |
| Hydrochlorothiazide | Hydrochlorothiazide | 128 | 43 |
| Gabapentin | Gabapentin | 121 | 34 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 113 | 28 |
| Warfarin Sodium | Warfarin Sodium | 106 | 15 |
| Simvastatin | Simvastatin | 104 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 96 | 20 |
| Famotidine | Famotidine | 89 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 89 | 19 |
| Eliquis | Apixaban | 73 | 13 |
| Montelukast Sodium | Montelukast Sodium | 73 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 72 | 19 |
| Potassium Chloride | Potassium Chloride | 67 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 64 | 20 |
| Ozempic | Semaglutide | 63 | suppressed |
| Allopurinol | Allopurinol | 61 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 61 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 60 | 15 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 58 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 57 | 13 |
| Carvedilol | Carvedilol | 56 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 53 | 18 |
| Ezetimibe | Ezetimibe | 51 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 48 | suppressed |
| Alprazolam | Alprazolam | 46 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 44 | 21 |
| Lorazepam | Lorazepam | 44 | suppressed |
| Mirtazapine | Mirtazapine | 44 | suppressed |
| Spironolactone | Spironolactone | 44 | 11 |
| Glimepiride | Glimepiride | 39 | suppressed |
| Jardiance | Empagliflozin | 39 | suppressed |
| Prednisone | Prednisone | 39 | 25 |
| Sertraline Hcl | Sertraline Hcl | 38 | 13 |
| Celecoxib | Celecoxib | 37 | 12 |
| Finasteride | Finasteride | 37 | 11 |
| Enalapril Maleate | Enalapril Maleate | 36 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 35 | 29 |
| Clonazepam | Clonazepam | 34 | suppressed |
| Irbesartan | Irbesartan | 34 | suppressed |
| Methylprednisolone | Methylprednisolone | 34 | 29 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 32 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 30 | 14 |
| Chlorthalidone | Chlorthalidone | 29 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 29 | suppressed |
| Azithromycin | Azithromycin | 28 | 25 |
| Atenolol | Atenolol | 27 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 27 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 26 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 26 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 25 | 22 |
| Quetiapine Fumarate | Quetiapine Fumarate | 25 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 23 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 23 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 23 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 22 | 16 |
| Fenofibrate | Fenofibrate Nanocrystallized | 21 | suppressed |
| Ibuprofen | Ibuprofen | 21 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 21 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 21 | suppressed |
| Pregabalin | Pregabalin | 21 | suppressed |
| Trulicity | Dulaglutide | 21 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 20 | suppressed |
| Fenofibrate | Fenofibrate | 20 | suppressed |
| Gemfibrozil | Gemfibrozil | 20 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 19 | suppressed |
| Unifine Pentips | Pen Needle, Diabetic | 18 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 18 | suppressed |
| Jantoven | Warfarin Sodium | 17 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 17 | suppressed |
| Xarelto | Rivaroxaban | 17 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 16 | suppressed |
| Cefdinir | Cefdinir | 16 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 16 | suppressed |
| Premarin | Estrogens, Conjugated | 16 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 16 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 15 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 14 | suppressed |
| Enbrel | Etanercept | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 13 | 12 |
| Glipizide | Glipizide | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | 11 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Dexamethasone | Dexamethasone | 12 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Mounjaro | Tirzepatide | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $436.10 · 23 records | Alexion Pharmaceuticals, Inc. | ABRYSVO, AREXVY, CRYSVITA, ELIQUIS, EVENITY, JARDIANCE, NURTEC ODT, OTEZLA, PENMENVY, PREVNAR 20, PROLIA, QULIPTA, REPATHA, SHINGRIX, STRENSIQ, TERIPARATIDE, Tymlos, UBRELVY, VOQUEZNA, VYNDAMAX, Veozah, Wegovy | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error